SEC (Category)
Filings
SEC Grouping
Select Year
| Filing | Description | Date | Format |
|---|---|---|---|
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer’s Disease | September 4, 2024 | ||
Recap of AAIC24 Conference Participation and Poster Presentations | August 28, 2024 | ||
IGC Announces Results of its 2024 Annual Stockholders Meeting | August 26, 2024 | ||
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer’s Disease | August 22, 2024 | ||
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist | August 20, 2024 | ||
RICHARD PRINS FORM 144 | August 12, 2024 | ||
RICHARD PRINS FORM 4 | August 12, 2024 | ||
FORM 10-Q | August 7, 2024 | ||
IGC Pharma Form 8-K | August 3, 2024 | ||
Desk of CEO Marijuana Reclass | July 25, 2024 |